Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Thyroid Cancer
Study Summary
This trial is researching whether or not the combination of these two drugs is effective in treating thyroid cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 65 with any prior treatment or over 65 and have had TKI treatment.I am at risk for liver damage from some medications.I haven't had chemotherapy or radiotherapy in the last 4 weeks and have recovered from any side effects.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.Your blood test results need to be within certain limits.I haven't taken steroids or immunosuppressants in the last 14 days.I have thyroid cancer that didn't respond to previous treatment and got worse in the last 13 months.I have thyroid cancer that didn't respond to previous treatment and got worse in the last 13 months.I am under 65 with any prior treatment or over 65 and have had TKI treatment.I can care for myself but may not be able to do active work.My organ and bone marrow functions are normal.I use a highly effective birth control method.I have had multiple treatments for my condition.I am 18 years old or older.I am 18 years old or older.My thyroid cancer has spread and didn't respond to RAI, worsening in the last 13 months.I have had any number of previous treatments.You have a known autoimmune disease that is currently active or suspected.I can take care of myself but might not be able to do active work.I have active cancer spread to my brain.You are currently taking any other experimental medications.
- Group 1: Ipilimumab alone for two weeks
- Group 2: Nivolumab alone for two weeks
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people total are involved in this experiment?
"This study is not recruiting patients at the moment. The listing for this clinical trial was created on September 20th, 2017 and last updated on February 18th, 2022. However, there are presently 240 other trials involving thyroid cancer patients and 796 studies utilising Nivolumab that are actively enrolling new participants."
Is Nivolumab currently cleared by the FDA?
"Nivolumab's safety is supported by Phase 2 data, but since there are no studies demonstrating efficacy, it received a score of 2."
What are the conditions that Nivolumab is known to be an effective treatment for?
"Nivolumab, which is sometimes used to counteract the effects of anti-angiogenic therapy, can also be an effective treatment for various other conditions such as malignant neoplasms and squamous cell carcinoma."
Are we able to enroll patients at this time?
"No, this study is not recruiting new participants at the moment. However, that may change in the future as the study's administrators last updated it on February 18th, 2022. There are currently 1036 other trials that are actively looking for test subjects."
Could you walk me through the other Nivolumab studies that have been conducted?
"Out of the 86 Phase 3 trials for Nivolumab, 796 are still active. In addition to the few locations running out of Pittsburgh, Pennsylvania, there are 43200 other centres researching this medication."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger